Ublituximab - TG Therapeutics
Alternative Names: BRIUMVI; EMAB-6; EMAB-603; LFB-R603; R603; Rituximab biobetter - TG Therapeutics; TG-1101; TG-20; TGTX-1101; Ublituximab-xiiy - TG Therapeutics; Utuxin™Latest Information Update: 08 Aug 2024
At a glance
- Originator LFB Biotechnologies; rEVO Biologics
- Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
- Class Antineoplastics; Biobetters; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Preregistration Submission Withdrawal Chronic lymphocytic leukaemia
- Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Neuromyelitis optica; Non-Hodgkin's lymphoma; Richter's syndrome
Most Recent Events
- 08 Aug 2024 Phase-I clinical trials in Multiple sclerosis (SC)
- 31 Jul 2024 TG Therapeutics terminates a phase Ib trial for B-cell lymphoma and Chronic lymphocytic leukaemia (Combination therapy, Monotherapy, Second-line therapy or greater) (IV) due to business decision (NCT04806035)
- 29 Feb 2024 Adverse events data from the phase IIIb ENHANCE trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)